Government asks justices to consider DOMA case 
Published: October 30, 2012
Tags: Defense of Marriage Act, DOMA, Donald Verrilli, U.S. Supreme Court
The Solicitor General is urging the U.S. Supreme Court to ignore the front of the line in the Defense of Marriage Act petitions for certiorari and instead agree to hear the last one filed.
Parents claim wrongful death due to energy drink
Published: October 26, 2012
Tags: California, Delaware, ENERGY DRINKS, false marketing, fraudulent concealment, Maryland, product liability, wrongful death
The parents of a 14-year-old girl have filed a wrongful death lawsuit alleging that the makers of the popular beverage Monster Energy were guilty of fraudulent concealment and negligence in marketing the drink to their child.
Watchdog group: Adverse drug events increase
Published: October 25, 2012
Tags: adverse events, FDA, prescription drugs
An independent watch dog group has reported a 23.8 percent increase in the number of reports of serious adverse events associated with the use of various medications during the first quarter of 2012 as compared to the same time period last year.
First lawsuits filed over meningitis outbreak
By:
Lisa Keen
Published: October 24, 2012
Tags: contamination, infection, Massachusetts, meningitis
The first lawsuits have been filed by plaintiffs claiming they have experienced symptoms of meningitis or contracted the bacterial infection after receiving contaminated steroid injections distributed by a Massachusetts-based company.
First trial pool Chantix case settles before trial
Published: October 22, 2012
Tags: Chantix, depression, Pfizer, prescription drugs, side effects, smoking, suicide
The first trial pool case in a multidistrict litigation against Pfizer’s anti-smoking medication Chantix settled last week, just days before the trial was to begin.
Federal Circuit ruling a win for biotech field
By:
Lisa Keen
Published: September 5, 2012
Tags: biotech, Federal Circuit, genetic testing, patent
In a second victory for the biotech industry in one year, the Federal Circuit has reinstated its ruling that a company’s isolation of human genetic material, and its process for using that material to determine the effectiveness of certain cancer therapies, meet the threshold test for patent-eligibility.
